10-Q: Candel Therapeutics Q3 2025: Clinical Progress & Funding

Candel Therapeutics reports positive clinical trial data for CAN-2409 in prostate and NSCLC, secures new $130M debt facility, and extends cash runway into Q1 2027.

Summary

• Net loss for the nine months ended September 30, 2025, was $8.7 million, a significant reduction from $41.1 million for the same period in 2024.
• Cash and cash equivalents stood at $87.0 million as of September 30, 2025.
• The company secured a new Loan and Security Agreement (Trinity LSA) for up to $130.0 million, with the first tranche of $50.0 million drawn on October 14, 2025.
• Existing cash and proceeds from the Trinity LSA are expected to fund operations into the first quarter of 2027.
• The pivotal Phase 3 clinical trial of CAN-2409 in newly diagnosed localized prostate cancer met its primary endpoint, demonstrating a statistically significant improvement in disease-free survival (DFS) (p=0.0155; HR 0.70).
• CAN-2409 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for newly diagnosed localized prostate cancer in May 2025.
• The Phase 2a clinical trial of CAN-2409 in Non-Small Cell Lung Cancer (NSCLC) showed a median overall survival (mOS) of 24.5 months (Cohort 1+2) and 21.5 months (Cohort 2 progressive disease), which is markedly longer than the 9.8-11.8 months reported for standard of care.
• CAN-3110 in recurrent high-grade glioma (HGG) showed mOS of 11.8 months (Arm A) and 12.0 months (Arm B) after a single injection, with some patients alive after prolonged follow-up.
• CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA for recurrent HGG.
• Clinical development of CAN-2409 in pancreatic ductal adenocarcinoma (PDAC) has been paused unless externally funded, due to portfolio prioritization.
• Research and development expenses increased by $5.0 million to $19.5 million for the nine months ended September 30, 2025, primarily due to increased manufacturing and regulatory costs for CAN-2409 programs.
• General and administrative expenses increased by $2.3 million to $13.0 million for the nine months ended September 30, 2025, driven by commercial readiness costs and employee-related expenses.
• The expiration date for Series B Warrants and Conditional Series B Warrants was extended from November 2025 to September 2027.

Sentiment

Score: 8

Explanation: The company reported strong positive clinical data for its lead candidates, particularly in prostate cancer and NSCLC, and secured substantial new financing, extending its cash runway. While still incurring losses and pausing one program, the clinical progress and improved liquidity are significant positive developments.

Positives

• CAN-2409 Phase 3 prostate cancer trial met its primary endpoint, demonstrating statistically significant improvement in disease-free survival (DFS) (p=0.0155; HR 0.70).
• CAN-2409 showed statistically significant improvement in prostate cancer-specific DFS (p=0.0046; HR 0.62).
• Statistically significant increase in the proportion of patients achieving a prostate-specific antigen (PSA) nadir (<0.2 ng/ml) was observed in the CAN-2409 arm (67.1% vs. 58.6%; p=0.0164).
• Statistically significant increase in the proportion of patients with a pathological complete response in 2-year post-treatment biopsies (80.4% in CAN-2409 arm vs. 63.6% in control arm; p=0.0015).
• CAN-2409 was generally well tolerated with most common adverse events being mild to moderate flu-like symptoms, fever, and chills.
• FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for CAN-2409 for newly diagnosed, localized prostate cancer in May 2025.
• CAN-2409 Phase 2a NSCLC trial showed median overall survival (mOS) of 24.5 months (Cohort 1+2) and 21.5 months (Cohort 2 progressive disease), which is markedly longer than the 9.8-11.8 months reported for standard of care.
• 37% of NSCLC patients with progressive disease were still alive > 24 months after CAN-2409 treatment.
• CAN-3110 recurrent HGG trial showed mOS of 11.8 months (Arm A) and 12.0 months (Arm B) after a single injection, with some patients alive after prolonged follow-up (59.2 and 42.4 months).
• FDA granted Fast Track Designation for CAN-3110 for recurrent HGG.
• FDA granted Orphan Drug Designation for CAN-3110 for recurrent HGG.
• New $130.0 million term loan facility with Trinity Capital Inc. secured, with $50.0 million drawn, extending cash runway into Q1 2027.
• Net loss for the nine months ended September 30, 2025, significantly decreased to $8.7 million from $41.1 million in the prior year.
• Interest income increased to $2.8 million for the nine months ended September 30, 2025, from $0.8 million in 2024.
• Change in fair value of warrant liability resulted in a $21.7 million decrease (income) for the nine months ended September 30, 2025.

Negatives

• CAN-2409 monotherapy in low-to-intermediate risk localized prostate cancer showed only a trend toward improvement in time to radical treatment and negative biopsies, but did not reach statistical significance.
• Decision to pause further clinical development of CAN-2409 in pancreatic ductal adenocarcinoma (PDAC) unless externally funded, due to portfolio prioritization.
• The company continues to incur significant operating losses and negative cash flows from operations, with an accumulated deficit of $200.9 million as of September 30, 2025.
• Additional capital will be required to fund operations beyond the first quarter of 2027.
• Research and development expenses increased by $5.0 million for the nine months ended September 30, 2025.
• General and administrative expenses increased by $2.3 million for the nine months ended September 30, 2025.

Risks

• The company has a limited operating history and has not generated any revenue from product sales, expecting to incur significant expenses and operating losses for the foreseeable future and may never achieve profitability.
• Substantial additional funding will be needed, and if unavailable on acceptable terms, product development programs or commercialization efforts may be delayed, reduced, or eliminated, or operations may cease.
• Incurred indebtedness and potential for additional debt could adversely affect financial condition.
• Business is dependent on the success of CAN-2409, CAN-3110, and other product candidates, all requiring additional development before regulatory approval and commercial launch.
• Preclinical studies and clinical trials may fail to adequately demonstrate the safety and efficacy of product candidates, preventing or delaying development, regulatory approval, and commercialization.
• Product candidates are based on a novel approach to cancer treatment, making it difficult to predict development time, cost, and regulatory approval outcomes.
• Even if marketing approval is received, product candidates may not achieve broad market acceptance, limiting revenue generation.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, potentially impairing revenue generation.
• The FDA's Special Protocol Assessment (SPA) for the Phase 3 CAN-2409 prostate cancer trial does not guarantee regulatory approval or a successful review process.
• Some product candidates are studied in third-party or investigator-sponsored clinical trials, over which the company has minimal or no control, potentially affecting marketing approval or regulatory exclusivities.
• Changes in product candidate manufacturing or formulation may result in additional costs or delays.
• Future public health crises, infectious disease outbreaks, geopolitical conflicts, or trade wars may adversely affect business and operations.
• Failure of government or third-party payors to provide adequate coverage, reimbursement, and payment rates for product candidates would limit revenue and profitability.
• Reliance on manufacturers; failure to produce required volumes on time or comply with regulations could lead to delays, inability to meet demand, and lost revenues.
• Transition of manufacturing operations to a third-party contract manufacturer may result in further delays or expenses and may not yield anticipated operating efficiencies.
• Rights to develop and commercialize certain product candidates are subject to third-party licenses; failure to comply with obligations could lead to loss of important intellectual property rights.
• Interim, topline, and preliminary clinical trial data may change as more patient data become available and are subject to regulatory audit and verification.
• Difficulty in enrolling patients could delay or prevent clinical trials and ultimately regulatory approval.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial profile, or result in negative consequences post-approval.
• Negative developments in the field of immuno-oncology, particularly viral immunotherapy, could damage public perception of product candidates.
• Inadequate funding for the FDA, SEC, and other government agencies could hinder their ability to perform normal business functions, negatively impacting the business.
• Ongoing obligations and continued regulatory review post-marketing approval may result in significant additional expense and limit how products are manufactured and marketed.
• Potential for substantial fines, criminal penalties, injunctions, or other enforcement actions for promoting unapproved or off-label uses.
• May not be able to file Investigational New Drug (IND) applications or amendments to commence additional clinical trials on expected timelines.
• Approved investigational products regulated as biologics may face competition from biosimilars.
• The size of the potential market for product candidates is difficult to estimate, and inaccurate assumptions could lead to smaller actual markets.
• Healthcare reform measures may have a material adverse effect on business and results of operations.
• Inability to establish sales, marketing, and patient support capabilities or enter into agreements with third parties could prevent successful commercialization.
• Failure to develop additional product candidates could limit commercial opportunity.
• Relationships with customers and third-party payors are subject to anti-kickback, fraud and abuse, and other healthcare laws and regulations, potentially leading to criminal sanctions or civil penalties.
• Potential liability if identifiable patient health information is obtained from clinical trials.
• Increasing use of social media could give rise to liability, data security breaches, or reputational damage.
• Internal computer systems, or those of third-party contractors, may fail or suffer cybersecurity incidents or data breaches.
• Operations or those of third parties may be affected by natural disasters, pandemics, war, or other catastrophic events.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Potential product liability exposure from clinical trials and commercial sales.
• Subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as import/export control laws, customs laws, and sanctions laws.
• Changes in tax laws or their implementation/interpretation may adversely affect business and financial condition.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited.
• Dependence on development and commercialization collaborators; failure to perform as expected could significantly reduce future revenue.
• Conflicts may arise with development and commercialization collaborators or licensors, potentially adverse to the company's interests.
• Reliance on third parties (independent clinical investigators, CROs) to conduct and sponsor clinical trials; failure to meet obligations may delay or impair regulatory approval.
• Completed related party transactions that may not have been conducted on an arms-length basis.
• Reliance on third parties requires sharing trade secrets, increasing the possibility of discovery or misappropriation.
• Difficulty and cost in protecting intellectual property; may not be able to ensure protection.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time.
• Limited foreign intellectual property rights and potential inability to protect intellectual property rights globally.
• Third-party claims of intellectual property infringement may prevent or delay product discovery and development efforts.
• Third parties may assert that employees or consultants have wrongfully used or disclosed confidential information or breached non-competition/non-solicitation agreements.
• May not be successful in obtaining or maintaining necessary rights to develop future product candidates on acceptable terms.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• Compliance with governmental patent agency requirements is necessary for obtaining and maintaining patent protection; non-compliance could reduce or eliminate protection.
• Issued patents covering product candidates could be found invalid or unenforceable or expire before marketing approval.
• If trademarks and trade names are not adequately protected, the company may not be able to build name recognition.
• The price of common stock may be volatile and fluctuate substantially.
• Raising additional capital through equity sales may cause dilution and stock price decline.
• Executive officers, directors, principal stockholders, and their affiliates exercise significant influence over the company.
• Anti-takeover provisions under charter documents and Delaware law could delay or prevent a change of control.
• Bylaws designate certain courts as the sole and exclusive forum for certain types of actions, potentially limiting stockholders' ability to obtain a favorable judicial forum.
• If securities analysts do not publish research or publish negative evaluations, the stock price could decline.
• Potential for securities litigation, which is expensive and could divert management's attention.
• The number of shares of common stock outstanding may increase substantially due to warrants.

Future Outlook

The company expects its existing cash and cash equivalents, combined with proceeds from the new Trinity LSA, to fund operating expenses and capital expenditure requirements into the first quarter of 2027. Key upcoming milestones include the initiation of a pivotal Phase 3 clinical trial of CAN-2409 in NSCLC in the second quarter of 2026, the submission of a Biologics License Application for CAN-2409 in prostate cancer in the fourth quarter of 2026, and the announcement of updated overall survival data for NSCLC in the first quarter of 2026. Additionally, immunological biomarker data for prostate cancer is anticipated in the third quarter of 2026, and mature median overall survival data for CAN-3110 Arm C is expected in the fourth quarter of 2026. The company will require additional capital to complete the Phase 3 NSCLC trial and further advance CAN-3110 and other product candidates.

Management Comments

• "We believe our existing cash and cash equivalents plus the proceeds from the loan and security agreement will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2027."
• "We are in ongoing dialogue with the FDA in preparation for the Company’s anticipated submission of a Biologics License Application for CAN-2409 in prostate cancer in the fourth quarter of 2026."
• "Based on these positive findings, we plan to initiate a pivotal phase 3 clinical trial of CAN-2409 in patients with progressive, metastatic, non-squamous NSCLC despite ICI treatment in the second quarter of 2026."
• "We expect to announce supportive data on prostate cancer-specific outcomes (prostate cancer-specific DFS, time to salvage anti-cancer therapy, and time to metastasis) after extended follow-up in the second quarter of 2026."
• "We expect to announce updated data on OS and long-term survival analysis in the first quarter of 2026 [for NSCLC]."
• "With a short follow up time for the most recently dosed patients and 2 additional patients still to be enrolled in arm C, we expect to present mature mOS data and an update on long-term survivors in the fourth quarter of 2026 [for CAN-3110]."
• "In October 2025, we decided to pause on further clinical development of CAN-2409 in PDAC, in the context of portfolio prioritization, unless externally funded through a grant or other non-dilutive external funding."

Industry Context

The company operates in the highly competitive biopharmaceutical industry, specifically focusing on immuno-oncology and novel viral immunotherapies for cancer treatment. Its approach utilizes genetically engineered viruses to induce immunogenic cell death and systemic anti-tumor immune responses. The industry is characterized by significant R&D investment, lengthy regulatory processes, and competition from major pharmaceutical and biotechnology companies (e.g., AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Regeneron, Roche/Genentech) and other viral immunotherapy developers (e.g., CG Oncology, J&J, Replimune, TILT, ImmVira). The company's strategy emphasizes optimizing vector, transgenes, and clinical indications while aiming to minimize systemic toxicity through local delivery. The limited number of globally or FDA-approved viral immunotherapies highlights the emerging nature and inherent challenges of this field.

Comparison to Industry Standards

• CAN-2409 Phase 2a NSCLC trial's observed median overall survival (mOS) of 24.5 months (Cohort 1+2) and 21.5 months (Cohort 2 progressive disease) is markedly longer than the 9.8-11.8 months of survival reported in published literature for similar patient populations receiving standard of care (SoC) second-line chemotherapy (Paz-Ares LG et al, J Clin Oncol 2024;42:2860-2872; Ahn MJ et al, J Clin Onc 2024;43:260-272).
• CAN-2409 Phase 2a pancreatic cancer trial showed an estimated mOS of 31.4 months in the CAN-2409 group versus only 12.5 months in the control group, indicating a substantial improvement over SoC.
• CAN-3110 recurrent HGG trial's updated mOS of 11.8 months (Arm A) and 12.0 months (Arm B) after a single injection compares favorably to the poor prognosis (expected overall survival < 6-9 months) for patients who previously failed SoC treatment.
• The observation that conventional MRI scans for CAN-3110 patients showed apparent tumor enlargement (pseudo-progression) despite extensive immune-mediated remodeling and tumor necrosis, underscores that conventional imaging criteria may underestimate the immunologic activity of viral immunotherapies compared to standard oncology imaging assessments.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any litigation or legal proceedings that, in the opinion of management, are probable to have a material adverse effect on the business. Litigation can have an adverse impact due to defense and settlement costs, diversion of management resources, and other factors.

Related Party Transactions

• Exclusive licensing agreement with Ventagen, LLC (Ventagen), an entity 49.5% owned by certain stockholders, including 47% by the company's founders (Estuardo Aguilar-Cordova and Laura Aguilar).
• Past lease agreements with Ellka Holdings, LLC (Ellka), owned and operated by Laura Aguilar and Estuardo Aguilar-Cordova and members of their immediate family.
• Amendment to Series B Warrants and Conditional Series B Warrants on October 14, 2025, involved holders including affiliates of Paul Manning and Chris Martell, who are directors of the company.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises and warrant exercises. Stock price volatility. Influence of executive officers, directors, and principal stockholders on corporate matters. Anti-takeover provisions could limit ability to influence corporate control.
• Patients: Potential for new, effective treatments for prostate cancer, NSCLC, and HGG if product candidates receive regulatory approval. Risk of side effects from novel therapies. Pause in PDAC development means no immediate new treatment option from Candel for those patients.
• Employees: Continued need to attract and retain qualified personnel for R&D, clinical, manufacturing, and administrative functions. Potential for growth in employee numbers.
• Creditors: New debt facility with Trinity Capital Inc. provides security interest in substantially all assets. Existing SVB loan repaid.
• Regulatory Bodies: Ongoing dialogue with FDA for BLA submission. Compliance with various regulatory requirements (GCP, cGMP, privacy laws).

Next Steps

• Announce supportive data on prostate cancer-specific outcomes (disease-free survival, time to salvage anti-cancer therapy, and time to metastasis) after extended follow-up in the second quarter of 2026.
• Announce immunological biomarker data from a supportive experimental medicine clinical trial of CAN-2409 in localized prostate cancer in the third quarter of 2026.
• Initiate a pivotal Phase 3 clinical trial of CAN-2409 in patients with progressive, metastatic, non-squamous NSCLC despite immune checkpoint inhibitor (ICI) treatment in the second quarter of 2026.
• Announce updated data on overall survival (OS) and long-term survival analysis for NSCLC in the first quarter of 2026.
• Submit a Biologics License Application (BLA) for CAN-2409 in prostate cancer in the fourth quarter of 2026.
• Present mature median overall survival (mOS) data and an update on long-term survivors for CAN-3110 Arm C in the fourth quarter of 2026.
• Continue to design additional novel viral immunotherapy candidates using the proprietary enLIGHTEN Discovery Platform.
• Seek additional capital to complete the Phase 3 trial for CAN-2409 in NSCLC or to further advance the development of CAN-3110 and other product candidates.

Key Dates

Recommendation

Candel Therapeutics has reported compelling positive clinical data for its lead product candidates, CAN-2409 in prostate cancer (meeting primary endpoint in Phase 3) and NSCLC (markedly longer mOS than SoC), and CAN-3110 in recurrent HGG (improved mOS compared to poor prognosis). The FDA's RMAT designation for CAN-2409 in prostate cancer further validates its potential. The company has also significantly strengthened its financial position by securing a new $130 million debt facility, extending its cash runway into Q1 2027, and substantially reducing its net loss year-over-year. While development in PDAC is paused and the company remains pre-revenue with ongoing R&D expenses, the strong clinical progress, regulatory designations, and improved liquidity suggest a positive trajectory and significant upside potential for investors willing to take on the inherent risks of a clinical-stage biotech. The upcoming BLA submission and Phase 3 NSCLC trial initiation are key catalysts.

Keywords

Candel Therapeutics, CAN-2409, CAN-3110, viral immunotherapy, oncolytic virus, prostate cancer, NSCLC, non-small cell lung cancer, glioblastoma, HGG, recurrent high-grade glioma, RMAT, Fast Track Designation, Orphan Drug Designation, clinical trials, biopharmaceutical, oncology, gene therapy, SEC filing, 10-Q, financial results, debt financing, equity financing, drug development, immunotherapy, cancer treatment, biotech, pharmaceutical, clinical stage, pipeline, intellectual property, regulatory approval, cash runway, operating loss, research and development, commercialization, corporate governance, risk factors